On April 1, 2026, the FDA approved Eli Lilly’s Foundayo, the second oral GLP‑1 for weight loss – offering fewer administration restrictions and achieving one of the fastest new‑drug approvals in decades.…
On March 26, 2026, the FDA approved Awiqli® (insulin icodec abae) from Novo Nordisk – the first once‑weekly basal insulin for adults with type 2 diabetes. This milestone represents a meaningful shift in…
Novo Nordisk recently received FDA approval to bring its oral semaglutide formulation, Rybelsus, under the Ozempic brand – aligning oral and injectable semaglutide for type 2 diabetes under a single, highly recognized name…
On February 24, 2026, Novo Nordisk announced it will significantly reduce the wholesale acquisition cost (WAC) of several of its GLP‑1 therapies, effective January 1, 2027…
On February 20, 2026 the U.S. Supreme Court struck down tariffs imposed under the International Emergency Economic Powers Act (IEEPA), holding that Congress did not delegate authority to the President to…
